Results 181 to 190 of about 76,100 (290)

Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations

Annals of Neurology, Volume 98, Issue 5, Page 1044-1056, November 2025.
Objectives To examine volumetric magnetic resonance imaging (vMRI) in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), compared to multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and healthy controls (HC). Methods Standardized vMRI in MOGAD were compared to age, sex, and disease duration matched MS (5:1),
Amy Kunchok, Moein Amin, Tatchaporn Ongphichetmetha, Mengke Du, Robert Bermel, Tucker Harvey, Justin R. Abbatemarco, Stephen E. Jones, Jeffrey A. Cohen, Daniel Ontaneda, Kunio Nakamura   +10 more
wiley   +1 more source

Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects. [PDF]

Mult Scler, 2023
Samadzadeh S, Olesen MN, Wirenfeldt M, Möller S, Misu T, Soelberg K, Frederiksen JL, Heegaard S, Mariotto S, Fujihara K, Ruprecht K, Andersen TL, Marignier R, Lillevang ST, Flanagan EP, Pittock SJ, Pittock SJ, Kim HJ, Bennett JL, Paul F, Sorensen GL, Weinshenker BG, Lassmann H, Asgari N.   +23 more
europepmc   +1 more source

AAV‐Based Intracerebral Administration of BDNF Promotes Myelin Repair and Cognitive Improvement After Cuprizone‐Induced Demyelination

Glia, Volume 73, Issue 11, Page 2189-2205, November 2025.
Main Points AAV‐BDNF improves cognitive performance after cuprizone‐induced demyelination. BDNF promotes OPC maturation and enhances remyelination in the corpus callosum. Mitochondrial integrity is preserved through reduced swelling and improved morphology.
Yousra El Ouaamari, Leonardo Ricciardi, Sanne van der Heijden, Antonia Peter, Jorrit De Waele, Jasper Van den Bos, Debby Van Dam, Elke Calus, Sarah Kuhn, Waleed Marei, Yvonne Dombrowski, Marleen Verhoye, Peter Ponsaerts, Inez Wens, Nathalie Cools   +14 more
wiley   +1 more source

Extracellular Vesicles in Chronic Demyelinating Diseases: Prospects in Treatment and Diagnosis of Autoimmune Neurological Disorders. [PDF]

Life (Basel), 2022
Ovchinnikova LA, Zalevsky AO, Lomakin YA.   +2 more
europepmc   +1 more source

Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease

, 1990
Stephen D. Miller, S J Gerety, Mary K. Kennedy, Jeffrey D. Peterson, John L. Trotter, Vincent K. Tuohy, Carl Waltenbaugh, Mauro C. Dal Canto, Howard L. Lipton   +8 more
openalex   +1 more source

Information Theory Analysis of CTX Shows Consistent Clinical Presentation

Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Cerebrotendinous xanthomatosis (CTX) is a rare, metabolic disorder caused by pathogenic variants in CYP27A1. The classic clinical presentation includes infantile‐onset chronic diarrhea, juvenile‐onset bilateral cataracts, with development of tendon xanthomas and progressive neurological dysfunction.
Jennifer Hanson, Penelope E. Bonnen
wiley   +1 more source

Recent topic.10.Demyelinate disease.

, 1992
西谷 裕
openalex   +2 more sources

Aryl Hydrocarbon Receptor in Health and Disease

MedComm, Volume 6, Issue 11, November 2025.
Based on the structure and ligands of AhR, this review introduces the AhR‐related signaling pathways and their roles in health and diseases. Agonists and antagonists of AhR as well as new strategies for treatment using the microbial–AhR axis are summarized. A prospect was made for the future use of AhR as a therapeutic target.
Haonan Li, Yufeng Fan, Jizheng Liu, Shumin Dong, Bin Wen, Yunfei Zhang, Xiaocui Wang, Xuemei Duan, Ying Hu, Ze Yan, Huifeng Shang, Yukai Jing   +11 more
wiley   +1 more source

Minimal Clinically Important Differences in Measuring Treatment Effects in CIDP: History, Current Use, Limitations, and Prospects

Muscle &Nerve, Volume 72, Issue 5, Page 1042-1051, November 2025.
ABSTRACT Outcome measures are essential for evaluating treatment effects and disease progression in chronic inflammatory demyelinating polyneuropathy (CIDP). The concept of the minimal clinically important difference (MCID), which represents the smallest change in a measure deemed clinically meaningful, has become increasingly important in CIDP ...
Yusuf A. Rajabally, Kabir K. Nazeer, Young Gi Min   +2 more
wiley   +1 more source

Neuroophthalmological evaluation in primary inflammatory demyelinating diseases with special reference to optic neuritis: A prospective study. [PDF]

J Family Med Prim Care
Khetan A, Verma R, Chakraborty R, Garg RK, Malhotra HS, Sharma PK, Kumar N, Uniyal R, Pandey S, Rizvi I.   +9 more
europepmc   +1 more source